<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230786</url>
  </required_header>
  <id_info>
    <org_study_id>KBP042/CD/003</org_study_id>
    <secondary_id>2017-001061-24</secondary_id>
    <nct_id>NCT03230786</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KeyBioscience AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KeyBioscience AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II
      trial of twelve weeks of KBP-042 administered as daily s.c. injections in subjects with Type
      2 Diabetes Mellitus with inadequate glycaemic control while treated with a stable dose of
      metformin.

      The trial is planned to be performed in Czech Republic, Denmark, Moldova, Poland, Romania and
      United Kingdom
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 23, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in blood HbA1c at 12 weeks versus placebo.</measure>
    <time_frame>At 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight at 12 weeks versus placebo.</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting serum glucose at 12 weeks versus placebo</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting serum insulin at 12 weeks versus placebo</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting serum glucagon at 12 weeks versus placebo</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reaching a level of HbA1c below 7.0% (53 mmol/mol) at 12 weeks versus placebo</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD for 12 weeks as add-on to metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15µg KBP-042 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30µg KBP-042 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 30µg KBP-042 QD for 12 weeks as add-on to metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50µg KBP-042 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 50µg KBP-042 QD for 12 weeks as add-on to metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daily injection of KBP/placebo for 12 weeks as add-on to metformin</intervention_name>
    <description>Daily subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>15µg KBP-042 QD</arm_group_label>
    <arm_group_label>30µg KBP-042 QD</arm_group_label>
    <arm_group_label>50µg KBP-042 QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, 18-75 years of age, both inclusive, at the time of the first
             screening visit. Women must be either using adequate, highly effective methods of
             contraception, be post-menopausal or be considered sterile due to tubal ligation or
             other surgical procedures at the time of randomization. Sexually active men with a
             female partner of childbearing potential must agree in the use of highly effective
             method of contraception by the female partner throughout the trial period.

          2. Subjects with type 2 diabetes mellitus diagnosis whose HbA1c levels are ≥7.0% and
             ≤10.0% (53 mmol/mol to 86 mmol/mol, respectively) at screening.

          3. Stable therapy (for at least 90 days prior to randomization) with metformin.

          4. Body mass index (BMI) ≥ 25.0 kg/m², and ≤ 45.0 kg/m².

          5. The subject is able to understand and comply with protocol requirements.

          6. The subject is able and willing to give written informed consent.

        Exclusion Criteria:

          1. Investigator considering the subject inappropriate for inclusion in the study based on
             medical interview and/or physical examination.

          2. Past or present significant co-morbidity (other than type 2 diabetes mellitus)
             including, but not limited to: Active liver disease (other than asymptomatic
             non-alcoholic fatty liver disease), significant renal disease (including creatinine
             clearance &lt; 45 ml/min by the Modification of Diet in Renal Disease (MDRD) method,
             congestive heart failure (NYHA class III or IV), myocardial infarction within the past
             12 months, unstable angina pectoris.

          3. Prior treatment in clinical trials with dual amylin and calcitonin receptor agonists
             (DACRAs).

          4. Currently receiving medical treatment for obesity.

          5. History of bariatric surgery.

          6. Current alcohol abuse.

          7. Current medical non-metformin anti-diabetic therapy, including SGLT2-inhibitors,
             DPP4-inhibitors (dipeptidyl peptidase 4 inhibitors), GLP-1 (Glucagon-like peptide 1)
             analogues, insulin and sulfonylureas, for a period of 90 days prior to randomization.

          8. Use of thiazolidinediones (glitazones) lasting for more than one month within 90 days
             of randomization.

          9. Regular use of insulin or insulin analogues.

         10. History or presence of sensitivity or allergy to the study drug or drugs, to their
             components, or drugs of these classes or a history of drug or other allergy that
             contraindicates participation.

         11. History of sarcoma or other malignancy within the past five years, except adequately
             treated basal cell or squamous cell carcinoma of the skin, or resected cervical atypia
             or carcinoma in situ.

         12. Participation in a study trial with any investigational new drug (new chemical entity)
             within 90 days prior to the start of the study.

         13. Pregnant females as determined by positive serum or urine human chorionic gonadotropin
             (hCG) test at screening or prior to randomization or during the treatment phase of the
             trial.

         14. Breast-feeding women.

         15. Known positive test results for hepatitis C antibodies, hepatitis B surface antigen,
             and HIV at screening.

         16. ALT (alanine transaminase) or AST (aspartat transaminase) &gt; 2.5 times the upper limit
             of normal at screening or other clinically significant liver function test
             abnormalities.

         17. Clinically significant ECG abnormalities, as judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vdoviak Miroslav MUDr. - Interní Ambulance</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 17</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague 2</city>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and experimental Medicine</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interní a Diabetologická ambulance, Clintrial s.r.o</name>
      <address>
        <city>Praha</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endokrinologicky Ústav</name>
      <address>
        <city>Praha</city>
        <zip>113 94</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabet2 s.r.o</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interní a Diabetologická ambulance</name>
      <address>
        <city>Uherské Hradiště</city>
        <zip>68 601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologická a Obezitologická ambulance</name>
      <address>
        <city>České Budějovice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital, Endokrinologisk Afdeling</name>
      <address>
        <city>Bispebjerg</city>
        <state>Copenhagen NV</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica</name>
      <address>
        <city>Ballerup</city>
        <state>Copenhagen</state>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica</name>
      <address>
        <city>Aalborg</city>
        <state>Jutland</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital, Endocrinlogy Department</name>
      <address>
        <city>Aarhus</city>
        <state>Jutland</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus</name>
      <address>
        <city>Esbjerg</city>
        <state>Jutland</state>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica</name>
      <address>
        <city>Vejle</city>
        <state>Jutland</state>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holbæk Sygehus</name>
      <address>
        <city>Holbæk</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rtl Sm Srl/Scr</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rtl Sm Srl</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych PI-House sp. z o.o.</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska Piotr Kubalski</name>
      <address>
        <city>Grudziądz</city>
        <zip>86-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczno</name>
      <address>
        <city>Kraków</city>
        <zip>31-261</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski M. Horodecki (budynek Medicus)</name>
      <address>
        <city>Opole</city>
        <zip>45-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Hygea</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED</name>
      <address>
        <city>Warsaw</city>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer</name>
      <address>
        <city>Łódź</city>
        <zip>90-074</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Policlinica CCBR S.R.L.</name>
      <address>
        <city>Bucharest</city>
        <zip>030463</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutului Național de Diabet, Nutriție și Boli Metabolice &quot;Prof.Dr. N.C. Paulescu&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C Nicodiab S.R.L.</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Sfinx Medica S.R.L.</name>
      <address>
        <city>Constanţa</city>
        <zip>900412</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Mediab S.R.L.</name>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Mediab S.R.L.</name>
      <address>
        <city>Târgu-Mureş</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Pancras</name>
      <address>
        <city>London</city>
        <zip>WC1X 8QD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>KBP-042</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not to be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

